Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma

Pediatric Hematology and Oncology
Suguru UemuraKazumoto Iijima

Abstract

The outcomes of osteosarcoma with poor prognostic factors, such as poor responders, metastatic disease at diagnosis, and relapsed or refractory disease, are poor. We reviewed the clinical records of the patients diagnosed with osteosarcoma at our institute between 2004 and 2018 who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in our institute. Ten patients of osteosarcoma with poor responder, refractory status, and metastatic disease at diagnosis received high-dose chemotherapy followed by ASCT. Four patients underwent high-dose chemotherapy followed by ASCT with the conditioning regimen consisted of thiotepa and melphalan (MEL). Five patients underwent high-dose chemotherapy followed by ASCT with the conditioning regimen consisted of intravenous busulfan (BU) and MEL. One patient underwent tandem high-dose chemotherapy followed by ASCT with BU and MEL followed by carboplatin and etoposide. None of the ten patients died of regimen related toxicities. None of the five patients with poor responders who underwent high-dose chemotherapy followed by ASCT as part of consolidation therapy died of disease after ASCT. High-dose chemotherapy followed by ASCT might be effective for poor responder...Continue Reading

References

Apr 1, 1996·Annals of Medicine·A Atra, R Pinkerton
Sep 22, 1999·Bone Marrow Transplantation·J PerentesisN Ramsay
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F FagioliE Madon
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano FerrariGaetano Bacci
May 20, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S SmelandG Saeter
Apr 13, 2004·Current Opinion in Oncology·Paul A Meyers
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A MeyersHolcombe Grier
Apr 8, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emilios E PakosJohn P A Ioannidis
Aug 19, 2009·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ji Won LeeHee Young Shin
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S IsakoffRichard Gorlick

❮ Previous
Next ❯

Citations

Nov 1, 2020·Clinical Pharmacokinetics·Rachael LawsonStefanie Hennig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.